Saturday, December 7, 2013

Aralen (Chloroquine Phosphate) Tablets

US FDA has modified the section of Warnings and adverse reactions of Aralen (Chloroquine Phosphate) Tablets
The warnings section mentions that - retinopathy/maculopathy, as well as macular degeneration have been reported and irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related. Risk factors for the development of retinopathy include age, duration of treatment, high daily and/or cumulated doses.

The adverse reactions section mentions that maculopathy and macular degeneration have been reported and may be irreversible.

No comments:

Post a Comment